Clinical trials: Schizophrenia Patients
Diabetes Mellitus, Schizophrenia
Diabetes Prevention Program in Schizophrenia [DPPS]
Diabetes is 2-5 times more common in schizophrenia and it is a preventable; but the current diabetes prevention guidelines are not suitable for implementation in the severely mentally ill population.
- Trial name
- NCT00182494
- Testing
- Modified diabetes prevention protocol & Metformin
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Hamilton Health Sciences Corporation
Schizophrenia
Aggressive Acts Among Patients With Schizophrenia
The purpose of this series of study has a many-fold intention depicted as follows: to describe and characterize schizophrenic patients' aggressive acts in hospital and community, to identify and specify heterogeneity in their…
- Trial name
- NCT00172497
- Where
- Taiwan
- Volunteers
- 450 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Schizoaffective Disorder
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
The study involves a six-month, double-blind protocol during which eighty patients, across three sites around the country, will be randomly assigned to receive clozapine or olanzapine.
- Trial name
- NCT00179231
- Testing
- olanzapine vs. clozapine
- Volunteers
- 80 people
- Sponsor
- Vanderbilt University
Depressive Disorders, Schizophrenia
Psychiatric Day Hospital Treatment
The aim of the study was to compare the effectiveness of acute psychiatric day care to conventional inpatient care within a cross-national multi-site randomised controlled trial.
- Conditions
- Depressive Disorders, Schizophrenia, Anxiety Disorders, Personality Disorders
- Trial name
- NCT00153959
- Testing
- acute psychiatric day care
- Where
- 5 sites in Czechia, Germany and 3 more
- Sponsor
- Technische Universität Dresden
Schizophrenia, Chinese Han People
Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Several chromosomal loci obtained from genetic linkage studies have been reported of relating to schizophrenia. These areas include of 1q32-41, 6p24-21, 8p22-21, 15q13-14, and 22q11-12.
- Trial name
- NCT00155701
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Chinese Han People
Mutation Screening and Translocation Detection of DISC1 Gene in Schizophrenia
Several chromosomal loci obtained from genetic linkage studies have been reported of relating to schizophrenia. These areas include of 1q32-41, 6p24-21, 8p22-21, 15q13-14, and 22q11-12.
- Trial name
- NCT00155818
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia, First-Episode
Optimization of Acute Treatment in First Episode Schizophrenia
The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol.
- Trial name
- NCT00157378
- Testing
- Risperidone, Haloperidol
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Schizophrenic Disorders
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
The study is a randomized clinical trial investigating the efficacy of a comprehensive psychological intervention for the treatment of first episode schizophrenia
- Trial name
- NCT00161408
- Testing
- cognitive behavioural therapy, psychoeducation
- Where
- 5 sites in Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen
Akathisia
Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation
Akathisia is a movement disorder that is often a side effect of certain psychiatric drugs. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace.
- Trial name
- NCT00065286
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Dyskinesia, Schizophrenia
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Tardive dyskinesia is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. This study investigates whether the addition of the omega-3 fatty acid, ethyl-eicosapentaenoic acid (EPA) to…
- Trial name
- NCT00114595
- Testing
- eicosapentaenoic acid
- Where
- South Africa
- Volunteers
- 84 people
- Sponsor
- University of Stellenbosch